Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd.QNRX · Entity 7876 | Director · Chief Executive Officer | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quoin Pharmaceuticals Ltd.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ADSsSEC Table I · non-derivative | Direct | 37,713 |
Reported balance
After 2026-08-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-31 · Purchase · Acquired 20,490 · Balance 37,713 F1: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. F2: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. |
| Ordinary Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.10 | Direct | 10,245 |
Reported balance
After 2026-08-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-31 · Purchase · Acquired 10,245 · Balance 10,245 F2: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. F3: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap. F4: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome. F1: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
F2: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.
F3: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
F4: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 01:39 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseOrdinary Warrants (Right to Buy) · Derivative | 10,245 | Not disclosed Strike: $6.10 | Not disclosed |
DisclosureSEC source: 0001104659-26-104404 · tm2624615-3_4seq1.xml · derivative · entry 2 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,245 Underlying: ADS · 10,245 shares Expires not disclosed F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. F2 · price: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. F3 · derivative.exercise_date: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap. F4 · derivative.expiration_date: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome. F1 · derivative.underlying: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 01:39 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseADSs | 20,490 | $4.88 | $99,991.20 |
DisclosureSEC source: 0001104659-26-104404 · tm2624615-3_4seq1.xml · nonDerivative · entry 1 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,713 F1 · security: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 22:18 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | GrantShare Option (Right to Buy) · Derivative | 318,750 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001104659-26-011616 · tm265448-5_4seq1.xml · derivative · entry 1 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,750 Underlying: ADS · 318,750 shares Expires 2036-02-04 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. Read SEC document |
| May 29, 2025 Filed Jun 3, 2025 00:42 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | GrantShare Option (Right to Buy) · Derivative | 42,039 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0001104659-25-055634 · tm2516320-7_4seq1.xml · derivative · entry 1 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,039 Underlying: ADS · 42,039 shares Expires 2035-05-29 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. Read SEC document |
| May 29, 2025 Filed Jun 14, 2025 00:06 UTC Amendment | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | GrantShare Option (Right to Buy) · Derivative | 42,857 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0001104659-25-059529 · tm2518028-4_4aseq1.xml · derivative · entry 1 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,857 Underlying: ADS · 42,857 shares Expires 2035-05-29 F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025. Read SEC document |
| December 23, 2024 Filed Dec 27, 2024 22:16 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseSeries G Warrants (right to buy) · Derivative | 555,556 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001104659-24-132188 · tm2431988-3_4seq1.xml · derivative · entry 3 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 555,556 Underlying: ADS · 555,556 shares Expires 2029-12-24 F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap. Read SEC document |
| December 23, 2024 Filed Dec 27, 2024 22:16 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseSeries F Warrants (right to buy) · Derivative | 555,556 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001104659-24-132188 · tm2431988-3_4seq1.xml · derivative · entry 2 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 555,556 Underlying: ADS · 555,556 shares Expires 2026-12-23 F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap. Read SEC document |
| December 23, 2024 Filed Dec 27, 2024 22:16 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseOrdinary Shares | 555,556 | $0.45 | $250,000.20 |
DisclosureSEC source: 0001104659-24-132188 · tm2431988-3_4seq1.xml · nonDerivative · entry 1 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,808 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:47 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | GrantShare Option (Right to Buy) · Derivative | 536,603 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001104659-24-127237 · tm2430519-3_4seq1.xml · derivative · entry 1 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,603 Underlying: ADS · 536,603 shares Expires 2034-12-09 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 16:03 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseOrdinary Shares | 23,572 | $0.80 | $18,796.31 |
DisclosureSEC source: 0001104659-24-097254 · tm2423425-1_4seq1.xml · nonDerivative · entry 4 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,252 F1 · shares: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 16:03 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseOrdinary Shares | 8,200 | $0.75 | $6,134.42 |
DisclosureSEC source: 0001104659-24-097254 · tm2423425-1_4seq1.xml · nonDerivative · entry 3 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,680 F1 · shares: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 16:03 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseOrdinary Shares | 5,322 | $0.66 | $3,490.17 |
DisclosureSEC source: 0001104659-24-097254 · tm2423425-1_4seq1.xml · nonDerivative · entry 2 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,480 F1 · shares: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:03 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseOrdinary Shares | 800 | $0.62 | $495.20 |
DisclosureSEC source: 0001104659-24-097254 · tm2423425-1_4seq1.xml · nonDerivative · entry 1 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,158 F1 · shares: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F2 · balance_after: Effective July 18, 2023, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. Effective November 8, 2023, the Issuer completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand (60,000) ordinary shares to 1 ADS representing one (1) ordinary share. The amount of ordinary shares reported in this column includes ordinary shares previously included in the Reporting Person's Form 3, adjusted to reflect the number of ordinary shares resulting from the 1 for 60,000 reverse split effective November 8, 2023. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:11 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | GrantShare Option (Right to Buy) · Derivative | 80,965 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001104659-23-112568 · tm2329341-7_4seq1.xml · derivative · entry 1 Myers Michael · CIK 0001959547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,965 Underlying: American Depositary Share · 80,965 shares Expires 2033-10-26 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of October 26, 2024, 2025 and 2026 and 40% vesting on October 26, 2027. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.